Form 4: Eli Lilly Director Converts Pay to Stock

Eli Lilly Director Mary Lynne Hedley increased her direct beneficial ownership by acquiring 12.259 shares of common stock through a compensation deferral plan.

Summary

• Mary Lynne Hedley, a Director at Eli Lilly & Co (LLY), acquired 12.259 shares of common stock.
• The transaction occurred on October 20, 2025, with the shares valued at $808.96 per share.
• These shares were acquired by deferring cash compensation, which was converted into stock units under the Lilly Directors' Deferral Plan.
• The stock units will be settled in shares of common stock following her separation from service.
• Following this acquisition, Hedley directly beneficially owns 2,015.828 shares and indirectly owns 98 shares through a trust.

Sentiment

Score: 8

Explanation: The acquisition of shares through compensation deferral by a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and its shareholders.

Positives

• Director Mary Lynne Hedley increased her direct beneficial ownership in Eli Lilly & Co by acquiring 12.259 shares.
• The deferral of cash compensation into stock units demonstrates a strong alignment of the director's interests with those of shareholders, promoting long-term value creation.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service from Eli Lilly & Co.

Industry Context

This transaction represents a routine compensation deferral by a director, a common practice in corporate governance where executives and directors opt to receive equity instead of cash, aligning their financial interests with the long-term performance of the company. It does not indicate a specific industry trend or competitive development.

Comparison to Industry Standards

• The deferral of cash compensation into company stock by directors is a well-established practice across various industries, including the pharmaceutical sector, and is considered a standard mechanism for aligning director incentives with long-term shareholder value.
• This approach is commonly observed in large-cap companies, where directors often have the option to receive equity-based compensation, similar to practices at peer pharmaceutical companies, though specific comparative data is not provided in this filing.

Stakeholder Impact

• Shareholders: Increased alignment of the director's financial interests with the company's long-term performance, potentially fostering more shareholder-centric decision-making.

Next Steps

• Settlement of the acquired stock units into shares of common stock will occur following the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 filing details a routine compensation deferral by a director, which, while positive for governance alignment, is not significant enough in size or nature to warrant a change in investment recommendation for Eli Lilly & Co. It reflects standard practice rather than a new strategic development or material financial event.

Keywords

LLY, Eli Lilly, Director, Stock Acquisition, Insider Trading, Form 4, Compensation Deferral, Beneficial Ownership